Labcorp Launches New Test To Accelerate Path To Diagnosis Of Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Labcorp (NYSE:LH) has launched a new blood-based test, the ATN Profile, to accelerate the diagnosis of Alzheimer's disease. The test uses three blood biomarkers to detect the hallmarks of Alzheimer's disease. It is available through physicians for patients being evaluated for possible Alzheimer's disease or other cognitive impairments. The ATN Profile is expected to support more informed decision-making and improved personalized patient care.
October 11, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Labcorp's launch of the ATN Profile, a new blood-based test for Alzheimer's disease, could potentially boost the company's revenues as it fills a significant need in the healthcare sector.
The launch of Labcorp's ATN Profile test is a significant development as it addresses a critical need in the healthcare sector for faster and more accurate diagnosis of Alzheimer's disease. This could potentially lead to increased demand for the test, thereby boosting Labcorp's revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100